Botulinum neurotoxin
From Proteopedia
(Difference between revisions)
| Line 24: | Line 24: | ||
CBP contains a <scene name='67/671726/Cv/9'>light or catalytic domain</scene> (LC, residues 1-440, in magenta) and a <scene name='67/671726/Cv/10'>heavy</scene> (HC, residues 441-1296, in cyan) chain. CBP HC contains two modules: | CBP contains a <scene name='67/671726/Cv/9'>light or catalytic domain</scene> (LC, residues 1-440, in magenta) and a <scene name='67/671726/Cv/10'>heavy</scene> (HC, residues 441-1296, in cyan) chain. CBP HC contains two modules: | ||
the N-terminal <scene name='67/671726/Cv/11'>translocation domain</scene> (residues 441-875, in salmon) and the C-terminal <scene name='67/671726/Cv/12'>receptor-binding domain</scene> (residues 876-1296, in yellow). <scene name='67/671726/Cv/13'>Cofactor Zn+2 coordination site</scene>. <ref>PMID:9783750</ref> | the N-terminal <scene name='67/671726/Cv/11'>translocation domain</scene> (residues 441-875, in salmon) and the C-terminal <scene name='67/671726/Cv/12'>receptor-binding domain</scene> (residues 876-1296, in yellow). <scene name='67/671726/Cv/13'>Cofactor Zn+2 coordination site</scene>. <ref>PMID:9783750</ref> | ||
| + | |||
| + | ==3D structures of botulinum neurotoxin== | ||
| + | [[Botulinum neurotoxin 3D structures]] | ||
| + | |||
</StructureSection> | </StructureSection> | ||
| Line 37: | Line 41: | ||
**[[3v0a]], [[3v0b]] - CbCBN (mutant) + antibody + Type A progenitor toxin + Zn<br /> | **[[3v0a]], [[3v0b]] - CbCBN (mutant) + antibody + Type A progenitor toxin + Zn<br /> | ||
| - | *Type A Light Chain | + | *Type A Light Chain residues 1-425 |
**[[2g7k]], [[2g7p]], [[2g7q]], [[2imc]], [[3bwi]], [[3bon]], [[3qix]], [[2ise]], [[2isg]], [[2ish]], [[4ej5]] - CbCBN LC + Zn<br /> | **[[2g7k]], [[2g7p]], [[2g7q]], [[2imc]], [[3bwi]], [[3bon]], [[3qix]], [[2ise]], [[2isg]], [[2ish]], [[4ej5]] - CbCBN LC + Zn<br /> | ||
| Line 54: | Line 58: | ||
**[[3k3q]] - CbCBN LC + antibody + Zn<br /> | **[[3k3q]] - CbCBN LC + antibody + Zn<br /> | ||
| - | *Type A receptor-binding domain | + | *Type A translocation domain residues 547-871 |
| + | |||
| + | **[[6dkk]] - CbCBN <br /> | ||
| + | **[[6mhj]] - CbCBN (mutant) <br /> | ||
| + | |||
| + | *Type A receptor-binding domain residues 871-1296 | ||
**[[2vua]], [[3fuo]], [[5tpb]], [[5tpc]], [[5lr0]], [[5mk6]], [[5mk7]] – CbPBN <br /> | **[[2vua]], [[3fuo]], [[5tpb]], [[5tpc]], [[5lr0]], [[5mk6]], [[5mk7]] – CbPBN <br /> | ||
**[[4iqp]] – CbPBN (mutant)<br /> | **[[4iqp]] – CbPBN (mutant)<br /> | ||
**[[2vu9]] – CbPBN + polysaccharide + Mg<br /> | **[[2vu9]] – CbPBN + polysaccharide + Mg<br /> | ||
| - | **[[4jra]], [[5jlv]], [[5moy]] – CbCBN + synaptic vesicle glycoprotein 2C<br /> | + | **[[4jra]], [[5jlv]], [[5moy]], [[6es1]] – CbCBN + synaptic vesicle glycoprotein 2C<br /> |
**[[5jmc]] – CbCBN (mutant) + synaptic vesicle glycoprotein 2C<br /> | **[[5jmc]] – CbCBN (mutant) + synaptic vesicle glycoprotein 2C<br /> | ||
**[[4zjx]] – CbCBN + polypeptide inhibitor<br /> | **[[4zjx]] – CbCBN + polypeptide inhibitor<br /> | ||
**[[5l21]] – CbCBN + VHH-C2<br /> | **[[5l21]] – CbCBN + VHH-C2<br /> | ||
| - | *Type A Light+Heavy Chain translocation domain | + | *Type A Light+Heavy Chain translocation domain residues 1-877 |
**[[2w2d]], [[3bta]] - CbCBN LC+HC + Zn<br /> | **[[2w2d]], [[3bta]] - CbCBN LC+HC + Zn<br /> | ||
| Line 71: | Line 80: | ||
**[[1s0b]], [[1s0c]], [[1s0d]], [[1s0e]], [[1s0f]], [[1s0g]], [[1epw]] – CbCBN + Zn<br /> | **[[1s0b]], [[1s0c]], [[1s0d]], [[1s0e]], [[1s0f]], [[1s0g]], [[1epw]] – CbCBN + Zn<br /> | ||
| + | **[[6g5f]] – CbCBN + synaptotagmin-1<br /> | ||
**[[2np0]] – CbCBN + synaptotagmin-2 + Zn<br /> | **[[2np0]] – CbCBN + synaptotagmin-2 + Zn<br /> | ||
| + | **[[6g5g]] – CbCBN (mutant) + synaptotagmin-2 + Mg<br /> | ||
**[[1g9a]], [[1g9b]], [[1g9c]], [[1g9d]] – CbCBN + inhibitor + Zn<br /> | **[[1g9a]], [[1g9b]], [[1g9c]], [[1g9d]] – CbCBN + inhibitor + Zn<br /> | ||
**[[1i1e]] – CbCBN + doxorubicin + Zn<br /> | **[[1i1e]] – CbCBN + doxorubicin + Zn<br /> | ||
**[[1f31]] – CbPBN + trisaccharide + Zn<br /> | **[[1f31]] – CbPBN + trisaccharide + Zn<br /> | ||
| - | *Type B Light Chain | + | *Type B Light Chain residues 1-440 |
**[[2etf]], [[1f82]] - CbCBN LC + Zn<br /> | **[[2etf]], [[1f82]] - CbCBN LC + Zn<br /> | ||
| - | *Type B Light+Heavy Chain translocation domain | + | *Type B Light+Heavy Chain translocation domain residues 1-858 |
**[[2xhl]], [[3zuq]] - CbCBN LC+HC + Zn<br /> | **[[2xhl]], [[3zuq]] - CbCBN LC+HC + Zn<br /> | ||
| - | *Type B receptor-binding domain | + | *Type B receptor-binding domain residues 857-1291 |
| + | **[[6g5k]] - CbCBN + synaptotagmin-1 peptide<br /> | ||
**[[2nm1]], [[4kbb]] - CbCBN + synaptotagmin-2 peptide<br /> | **[[2nm1]], [[4kbb]] - CbCBN + synaptotagmin-2 peptide<br /> | ||
**[[1z0h]] – CbCBN <br /> | **[[1z0h]] – CbCBN <br /> | ||
| - | **[[5vid]] – CbCBN + mini-protein binder<br /> | + | **[[5vid]], [[5vmr]] – CbCBN + mini-protein binder<br /> |
*Type C Light Chain | *Type C Light Chain | ||
| Line 135: | Line 147: | ||
*Type F receptor-binding domain | *Type F receptor-binding domain | ||
| - | **[[3rsj]] - CbCBN <br /> | + | **[[3rsj]], [[3fuq]] - CbCBN <br /> |
*Type G Light Chain | *Type G Light Chain | ||
Revision as of 09:48, 16 April 2019
| |||||||||||
3D structures of botulinum neurotoxin
Updated on 16-April-2019
References
- ↑ Montecucco C, Molgo J. Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005 Jun;5(3):274-9. PMID:15907915 doi:http://dx.doi.org/10.1016/j.coph.2004.12.006
- ↑ Karalewitz AP, Fu Z, Baldwin MR, Kim JJ, Barbieri JT. Botulinum neurotoxin serotype C associates with dual ganglioside receptors to facilitate cell entry. J Biol Chem. 2012 Nov 23;287(48):40806-16. doi: 10.1074/jbc.M112.404244. Epub, 2012 Oct 1. PMID:23027864 doi:http://dx.doi.org/10.1074/jbc.M112.404244
- ↑ Zhang S, Berntsson RP, Tepp WH, Tao L, Johnson EA, Stenmark P, Dong M. Structural basis for the unique ganglioside and cell membrane recognition mechanism of botulinum neurotoxin DC. Nat Commun. 2017 Nov 21;8(1):1637. doi: 10.1038/s41467-017-01534-z. PMID:29158482 doi:http://dx.doi.org/10.1038/s41467-017-01534-z
- ↑ Zhang S, Masuyer G, Zhang J, Shen Y, Lundin D, Henriksson L, Miyashita SI, Martinez-Carranza M, Dong M, Stenmark P. Identification and characterization of a novel botulinum neurotoxin. Nat Commun. 2017 Aug 3;8:14130. doi: 10.1038/ncomms14130. PMID:28770820 doi:http://dx.doi.org/10.1038/ncomms14130
- ↑ Diel RJ, Kroeger ZA, Levitt RC, Sarantopoulos C, Sered H, Martinez-Barrizonte J, Galor A. Botulinum Toxin A for the Treatment of Photophobia and Dry Eye. Ophthalmology. 2018 Jan;125(1):139-140. doi: 10.1016/j.ophtha.2017.09.031. Epub, 2017 Oct 27. PMID:29110944 doi:http://dx.doi.org/10.1016/j.ophtha.2017.09.031
- ↑ Patil S, Willett O, Thompkins T, Hermann R, Ramanathan S, Cornett EM, Fox CJ, Kaye AD. Botulinum Toxin: Pharmacology and Therapeutic Roles in Pain States. Curr Pain Headache Rep. 2016 Mar;20(3):15. doi: 10.1007/s11916-016-0545-0. PMID:26879873 doi:http://dx.doi.org/10.1007/s11916-016-0545-0
- ↑ Costantin L, Bozzi Y, Richichi C, Viegi A, Antonucci F, Funicello M, Gobbi M, Mennini T, Rossetto O, Montecucco C, Maffei L, Vezzani A, Caleo M. Antiepileptic effects of botulinum neurotoxin E. J Neurosci. 2005 Feb 23;25(8):1943-51. doi: 10.1523/JNEUROSCI.4402-04.2005. PMID:15728834 doi:http://dx.doi.org/10.1523/JNEUROSCI.4402-04.2005
- ↑ Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol. 1998 Oct;5(10):898-902. PMID:9783750 doi:10.1038/2338
